BPC-157: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 26 sources cited
Overview
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protective protein found in human gastric juice. In animal studies it has shown healing effects in many tissue types (tendons, ligaments, muscles, bone, gut lining, brain, liver, and blood vessels), but no controlled human trial has been published. With over 100 peer-reviewed preclinical studies demonstrating robust therapeutic effects, it is arguably the most widely used and most extensively researched peptide in the biohacking and regenerative medicine communities. Its ability to accelerate healing in animal models whether administered locally near an injury or systemically has earned it a reputation as the single most versatile healing compound available.
Mechanism of Action
BPC-157's healing effects arise from the simultaneous activation of multiple synergistic repair pathways, which may explain its effects on such diverse tissue types in animal studies. These pathways were described in cell cultures and in animal models of injuries ranging from torn tendons to gut damage to traumatic brain injury; none has been confirmed in humans. **Angiogenesis and Growth Factor Upregulation:** In rat injury models and cultured endothelial cells, BPC-157 increases expression of the VEGF receptor VEGFR2 and activates VEGFR2-Akt-eNOS signaling, and it raised vascular endothelial growth factor (VEGF) expression in healing rat muscle and tendon. This drives the formation of new blood vessels (angiogenesis) at the injury site, ensuring adequate oxygen and nutrient delivery for tissue repair. In cultured rat tendon fibroblasts it also upregulates growth hormone receptor expression, potentially amplifying the body's endogenous GH signaling at the site of injury. **Cell Migration and Wound Closure:** BPC-157 activates the FAK-paxillin signaling pathway, which is central to cell adhesion and migration. By phosphorylating focal adhesion kinase (FAK) and its downstream target paxillin, BPC-157 promotes the migration of fibroblasts, endothelial cells, and other repair cells into the wound site. This accelerates both the proliferative and remodeling phases of healing. **Nitric Oxide System Modulation:** One of BPC-157's most distinctive properties is its complex interaction with the nitric oxide (NO) system. It protects endothelial NO synthase (eNOS) function, maintaining vascular tone and blood flow. It counteracts the effects of both NO system blockade (L-NAME) and NO system overstimulation (L-arginine excess), effectively acting as a NO system stabilizer. This is likely key to its vascular protective effects. **Neurotransmitter System Effects:** BPC-157 has significant effects on the dopaminergic system — it protects against dopaminergic neurotoxicity (in the MPTP mouse model), counteracts dopamine receptor supersensitivity, and has been shown to reverse behavioral effects of both dopamine agonists and antagonists. It also has GABAergic activity and interacts with the serotonergic system, contributing to its observed antidepressant and anxiolytic effects in animal models. **Gut-Specific Effects:** In rodent models of gastrointestinal injury, BPC-157 tightens epithelial tight junctions (reducing intestinal permeability / 'leaky gut'), downregulates pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), promotes mucosal repair and angiogenesis, and protects against NSAID-induced GI damage, alcohol-induced damage, and stress ulcers. It appears to work through the gut-brain axis, with systemic effects when administered orally. **Tendon and Ligament Repair:** In rat studies, BPC-157 promotes tendon fibroblast outgrowth, survival and migration (it did not directly increase their proliferation), improves collagen formation, and improves the biomechanical properties of healing tendons. It appears to shift the healing phenotype from scar formation toward more organized, functional tissue. In a rat Achilles tendon transection model, it improved load to failure and functional recovery compared with saline controls. Remarkably, BPC-157 demonstrates these healing effects regardless of whether it is administered locally at the injury site or systemically (in the animal studies, by intraperitoneal injection or in drinking water), suggesting it has both direct tissue effects and systemic signaling properties that recruit repair mechanisms to damaged areas.
BPC-157 Benefits: What the Research Shows
- Over 100 peer-reviewed preclinical studies report healing effects in animal models of tendon, ligament, muscle, bone, gut, brain, liver, heart, and blood vessel injury. Human evidence is limited to three small uncontrolled studies (30 participants in total), which a 2026 systematic review rated as very low certainty.
- Rat Achilles tendon transection model: BPC-157 improved tendon healing, with higher load to failure, greater stiffness (Young's modulus) and better functional scores than saline-treated controls (Staresinic et al., Journal of Orthopaedic Research, 2003).
- Counteraction of NSAID-induced damage in rats: BPC-157 strongly reduced the gastric, intestinal and liver lesions caused by diclofenac and counteracted the gastric lesions and liver damage caused by chronic ibuprofen. This has not been tested in humans.
- Neuroprotective effects in rodents: BPC-157 reduced the motor abnormalities and deaths caused by MPTP and reversed reserpine-induced catalepsy in mice (Parkinson's disease models), reduced damage from traumatic brain injury in mice, and improved functional recovery after spinal cord compression in rats.
- Experimental colitis: in rats, BPC-157 given by intraperitoneal injection reduced the extent of trinitrobenzene sulfonic acid (TNBS)-induced colonic damage and neutrophil infiltration in a dose-dependent manner. Intracolonic dosing was not effective at the dose tested.
- Alcohol-related damage: in mice, BPC-157 opposed acute alcohol intoxication and attenuated withdrawal, and in chronically alcohol-drinking rats it prevented and reversed portal hypertension and liver lesions.
- Corneal healing: Topical BPC-157 accelerated healing of corneal epithelial defects in a rat model, demonstrating ocular tissue repair capability.
- Muscle healing: in rats, BPC-157 accelerated the recovery of crushed gastrocnemius muscle, with less hematoma and edema, no leg contracture, and restored function compared to controls.
- Bone healing: BPC-157 improved healing of a segmental bone defect in rabbits, with callus and bone formation comparable to bone marrow or autologous cortical graft and more animals with fully healed defects than controls.
- Liver protection: in rats, BPC-157 reduced liver injury from carbon tetrachloride, bile duct and hepatic artery ligation, chronic alcohol, diclofenac and ibuprofen, with lower liver enzymes and improved histology.
BPC-157 Dosage
- Subcutaneous injection (localized healing): 250–500 mcg injected as close to the injury site as possible, 1–2 times daily. For tendon, ligament, or muscle injuries, inject subcutaneously directly over or adjacent to the affected area.
- Subcutaneous injection (systemic/gut healing): 250–500 mcg injected into the abdominal subcutaneous fat, 1–2 times daily. This is the standard protocol for gut healing, general recovery, and conditions where the injury site cannot be easily reached.
- Oral administration (GI-focused): 500 mcg capsules, 1–2 times daily on an empty stomach. Oral BPC-157 is primarily used for gastrointestinal issues (leaky gut, IBS, NSAID damage, ulcers) where direct contact with the GI mucosa is desired.
- Loading protocol for acute injuries: 500 mcg twice daily (morning and evening) for the first 2–4 weeks, then reduce to 250 mcg once daily for maintenance.
- Standard cycle for injury healing: 4–8 weeks for acute injuries (sprains, strains, post-surgical). 8–12 weeks for chronic conditions (tendinopathy, chronic gut issues, neurological recovery).
- Extended/indefinite low-dose protocol: 250 mcg once daily for chronic conditions, with no established upper limit on duration. Many users run BPC-157 continuously at maintenance doses for persistent issues.
- Stacking with TB-500: BPC-157 250–500 mcg + TB-500 250–750 mcg daily (or TB-500 2–2.5 mg twice weekly). This is the 'Wolverine stack' — the gold standard healing protocol combining angiogenesis (BPC) with cell migration and anti-inflammation (TB-500).
- Timing: No strict meal timing requirements for injectable BPC-157. Oral capsules should be taken on an empty stomach for best mucosal absorption.
- Injection technique: Use insulin syringes (29–31 gauge). For localized injection, insert the needle subcutaneously (not intramuscular) near but not directly into the injured tissue. Rotate sites within the target area.
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
BPC-157 Side Effects & Safety
Known Side Effects
- Injection site reactions — mild redness, swelling, or irritation at the injection site. Reported anecdotally by users; no human study has measured how often it happens. Usually resolves within 30 minutes.
- Mild nausea — reported occasionally, particularly with oral administration or high subcutaneous doses. Typically transient.
- Headache — reported infrequently, usually mild and resolving within the first few days of use.
- Dizziness — rare, possibly related to BPC-157's effects on blood pressure regulation through the NO system.
- Anecdotal reports of increased body temperature or flushing — likely related to enhanced angiogenesis and blood flow to healing tissues.
- Theoretical concern about promoting tumor angiogenesis — BPC-157 upregulates VEGF, which could theoretically support blood vessel growth in existing tumors. No evidence of this in preclinical studies, but individuals with active cancer should exercise caution.
- No serious toxicity was reported in published animal safety studies, and the three small human studies (30 people in total) reported no adverse events. That is too little to establish safety: the FDA states it lacks sufficient information to know whether BPC-157 would cause harm when administered to humans.
Safety Profile
BPC-157's safety record rests almost entirely on animal studies; no controlled human safety study has been published. In toxicity studies in mice, rats, rabbits and dogs it was well tolerated, and the research group that has studied it most reports that a lethal dose could not be reached (LD1 not achieved). The published preclinical safety evaluation found only mild local irritation and no genetic or embryo-fetal toxicity. The FDA has identified BPC-157 as a bulk drug substance that may present significant safety risks in compounding, citing possible immunogenicity and peptide-related impurities, and says it lacks sufficient information to know whether it would cause harm when administered to humans. BPC-157 is also prohibited in sport at all times under the WADA Prohibited List (S0, non-approved substances). The primary theoretical concern is VEGF-mediated angiogenesis in individuals with active malignancies — since BPC-157 promotes new blood vessel formation, it could theoretically support tumor vascularization. This has not been studied in humans, so it represents a reasonable precaution, and individuals with known or suspected cancer should consult oncology before use. Drug interactions have not been studied in humans. BPC-157 may counteract some NSAID-induced GI effects (which could be beneficial or could mask damage). It interacts with the dopaminergic system, so caution is warranted when combining with dopaminergic medications (levodopa, dopamine agonists, antipsychotics). It is not recommended during pregnancy or breastfeeding because there are no human reproductive safety data (one animal study found no embryo-fetal toxicity). BPC-157 does not suppress endogenous hormone production and does not require PCT (post-cycle therapy).
What to Expect
This timeline is drawn from user reports; no human trial has measured these effects. Days 1–3: Subtle anti-inflammatory effects may be noticeable — reduced pain, swelling, or stiffness at the injury site. Some users report improved gut comfort within the first 48 hours when using for GI issues. These early effects reflect BPC-157's rapid cytokine modulation. Week 1: Healing acceleration becomes apparent. Users with acute injuries often report noticeably faster recovery than expected. Gut healing patients frequently report reduced bloating, improved digestion, and decreased food sensitivities. Angiogenesis is beginning at the tissue level. Weeks 2–4: This is the primary healing window. Tendon and ligament injuries show significant improvement in pain and function. Range of motion increases. Gut permeability has only been measured in animal studies. Users recovering from surgery report faster-than-expected closure and reduced scarring. Chronic injuries that plateaued in recovery may break through. Weeks 5–8: Continued remodeling and maturation of healed tissue. The quality of repair improves — tissue becomes stronger and more organized. Chronic tendinopathy patients often report resolution of symptoms that persisted for months or years. Neurological recovery (post-TBI, neuropathy) is slower but progressive. Weeks 9–12+: Long-term remodeling continues. For chronic conditions, this extended period allows comprehensive tissue normalization. Many users transition to a lower maintenance dose or cycle off once primary healing goals are met. Residual benefits persist after discontinuation as the healed tissue maintains its improved state.
Common Stacks
TB-500 (Thymosin Beta-4)
The 'Wolverine Stack' — TB-500 provides cell migration via actin regulation and systemic anti-inflammation via NF-κB downregulation, perfectly complementing BPC-157's angiogenesis, growth factor upregulation, and NO system modulation. Together they address every phase of tissue repair.
GHK-Cu
GHK-Cu promotes collagen synthesis, anti-inflammatory gene expression, and antioxidant activity. Combined with BPC-157's vascular and growth factor effects, this stack provides comprehensive tissue remodeling support for aging, wound healing, and skin/connective tissue repair.
Ipamorelin
Ipamorelin stimulates GH release, and BPC-157 upregulates GH receptors — creating a synergistic loop where more GH is produced AND tissues are more responsive to it. Excellent for injury recovery and body composition.
AOD-9604
AOD-9604 has cartilage-regenerative properties that complement BPC-157's tendon and ligament healing effects. For comprehensive joint repair protocols, this combination covers articular cartilage, tendons, ligaments, and the associated vasculature.
Storage & Handling
Store lyophilized powder refrigerated at 36–46°F (2–8°C). For long-term storage (>3 months), freezing at -4°F (-20°C) is recommended and extends shelf life to 24+ months. After reconstitution with bacteriostatic water, refrigerate at 36–46°F and use within 4–6 weeks. Reconstitution: add 2 mL bacteriostatic water to a 10 mg vial for a concentration of 5 mg/mL (250 mcg per 0.05 mL/5 units on an insulin syringe). Gently swirl to dissolve — do not shake vigorously. Do not freeze reconstituted solution. Oral capsules should be stored at room temperature in a cool, dry place, away from moisture and direct sunlight.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025.
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
- The Prohibited List. World Anti-Doping Agency. 2026.
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003.
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011.
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017.
- Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009.
- Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014.
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020.
- Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013.
- Ilic S, Drmic D, Franjic S, et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci. 2011.
- Ilic S, Drmic D, Zarkovic K, et al. Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. Eur J Pharmacol. 2011.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014.
- Veljaca M, Lesch CA, Pllana R, et al. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther. 1995.
- Sikiric P, Marovic A, Matoz W, et al. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. J Physiol Paris. 1999.
- Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept. 2010.
- Perovic D, Kolenc D, Bilic V, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res. 2019.
- Sikiric P, Boban Blagaic A, Strbe S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024.
- Park JM, Lee HJ, Sikiric P, et al. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des. 2020.
- Blagaic AB, Blagaic V, Romic Z, et al. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. Eur J Pharmacol. 2004.
- Prkacin I, Separovic J, Aralicia G, et al. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol Paris. 2001.
- Lazić R, Gabrić N, Dekaris I, et al. Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats. Coll Antropol. 2005.
- Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008.
- Sebecić B, Nikolić V, Sikirić P, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone. 1999.
- Sikiric P, Seiwerth S, Grabarevic Z, et al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci. 1993.
BPC-157 Dosage Guide
Read the full guideRelated Peptides
Track BPC-157 in Your Protocol
Log your BPC-157 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free